Exelixis Inc

The metastatic prostate cancer market is projected to experience robust growth through 2036, valued at USD 11.5 billion in 2025 across seven major markets. The market is transitioning from conventional androgen deprivation therapy toward combination-based, biomarker-driven approaches, with novel therapies such as PSMA-targeted radioligand therapi...

Exelixis, a biotech company focused on cancer medicines, could potentially double by 2031. While its main product Cabometyx will face generic competition by early 2030, the company's promising pipeline candidate zanzalintinib could reach peak sales of $5 billion across multiple cancer indications, positioning it as a strong successor to drive fut...

Merck & Co. and Eisai announced that their Phase 3 LITESPARK-012 trial failed to meet primary endpoints for a triplet therapy combining Keytruda, Lenvima, and Welireg for advanced clear cell renal cell carcinoma. The failure caused Merck shares to fall 4.08%. However, the FDA approved Merck's new HIV treatment Idvynso on the same day, and analyst...

The article recommends three healthcare stocks trading under $50: Pfizer (PFE) at $27.45 with a low forward P/E of 9x and a strong oncology pipeline; Novo Nordisk (NVO) at $38.43 positioned to capitalize on the expanding weight-loss drug market with products like Wegovy; and Exelixis (EXEL) at $41.80, a focused oncology player with the successful...

Exelixis, a U.S.-based biotech company specializing in cancer treatments, is positioned for market-beating returns through its growing pipeline beyond its blockbuster cabozantinib drug. The company reported 57.9% EPS growth in 2025 and recently received FDA approval for zanzalintinib for metastatic colorectal cancer. With zanzalintinib in four ph...